New guidance from health technology assessment (HTA) agency NICE backs the use of Wainzua (eplontersen) to treat stage 1 or 2 ...

Alnylam Pharmaceuticals ALNY announced that the FDA has accepted its supplemental new drug application (sNDA) seeking the ...

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...

Amvuttra (vutrisiran) is a follow-up to Alnylam's earlier RNA interference (RNAi) ATTR amyloidosis therapy Onpattro (patisiran), which was cleared by NICE for NHS use in 2019, but offers a simpler ...

Vutrisiran is the generic name for AMVUTTRA ®, which is currently approved by the U.S. FDA for the treatment of the polyneuropathy of hereditary ATTR amyloidosis in adults. As part of the ...

Wolfe Research downgraded Alnylam (ALNY) to Underperform from Peer Perform with a $205 price target The firm cites expectations that the company will expand its approved Amvuttra into the much ...

Strong patient uptake of next-generation drug Amvuttra (for ATTR amyloidosis with polyneuropathy) is driving sales, accounting for $259 million of the quarter’s net product revenue, representing ...

Alnylam's Amvuttra followed these results with a once per quarter subcutaneous injection, which can be administered at home, with reductions of 28% and 33% for overall mortality and cardiovascular ...

Product revenue grew 34% year over year, mainly driven by sales of Amvuttra. Collaboration revenues dropped significantly, resulting in a plunge in total revenue. GAAP net loss per share was $0.87 ...